Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy
Tóm tắt
Melanoma of unknown primary (MUP) is considered different from melanoma of known primary (MKP), and it is unclear whether these patients benefit equally from novel therapies. In the current study, characteristics and overall survival (OS) of patients with advanced and metastatic MUP and MKP were compared in the era of novel therapy. Patients were selected from the prospective nation-wide Dutch Melanoma Treatment Registry (DMTR). The following criteria were applied: diagnosis of stage IIIc unresectable or IV cutaneous MKP (cMKP) or MUP between July 2012 and July 2017 and treatment with immune checkpoint inhibition and/or targeted therapy. OS was estimated using the Kaplan–Meier method. The stratified multivariable Cox regression model was used for adjusted analysis. A total of 2706 patients were eligible including 2321 (85.8%) patients with cMKP and 385 (14.2%) with MUP. In comparative analysis, MUP patients more often presented with advanced and metastatic disease at primary diagnosis with poorer performance status, higher LDH, and central nervous system metastases. In crude analysis, median OS of cMKP or MUP patients was 12 months (interquartile range [IQR] 5 – 44) and 14 months (IQR 5 – not reached), respectively (P = 0.278). In adjusted analysis, OS in MUP patients was superior (hazard rate 0.70, 95% confidence interval 0.58–0.85; P < 0.001). As compared to patients with advanced and metastatic cMKP, MUP patients have superior survival in adjusted analysis, but usually present with poorer prognostic characteristics. In crude analysis, OS was comparable indicating that patients with MUP benefit at least equally from treatment with novel therapies.
Tài liệu tham khảo
Verver D, van der Veldt A, van Akkooi A, Verhoef C, Grunhagen DJ, Louwman WJ (2019) Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: a dutch population-based study. Int J Cancer. https://doi.org/10.1002/ijc.32229
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, et al. (2017) Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. https://doi.org/10.3322/caac.21409
Song Y, Karakousis GC (2019) Melanoma of unknown primary. J Surg Oncol 119:232–241
Scott JF, Conic RZ, Thompson CL, Gerstenblith MR, Bordeaux JS (2018) Stage IV melanoma of unknown primary: a population-based study in the united states from 1973 to 2014. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2018.03.021
Smith JL Jr, Stehlin JS Jr (1965) Spontaneous regression of primary malignant melanomas with regional metastases. Cancer 18:1399–1415
Giuliano AE, Moseley HS, Morton DL (1980) Clinical aspects of unknown primary melanoma. Ann Surg 191:98–104
Panagopoulos E, Murray D (1983) Metastatic malignant melanoma of unknown primary origin: a study of 30 cases. J Surg Oncol 23:8–10
Anbari KK, Schuchter LM, Bucky LP, Mick R, Synnestvedt M, Dt G, Hamilton R, Halpern AC (1997) Melanoma of unknown primary site: presentation, treatment, and prognosis–a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer 79:1816–1821
Savoia P, Fava P, Osella-Abate S, Nardo T, Comessatti A, Quaglino P, Bernengo MG (2010) Melanoma of unknown primary site: a 33-year experience at the Turin Melanoma Centre. Melanoma Res 20:227–232
Cervinkova M, Kucerova P, Cizkova J (2017) Spontaneous regression of malignant melanoma - is it based on the interplay between host immune system and melanoma antigens. Anticancer Drugs 28:819–830
Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW, McCarthy WH (1991) Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 97:197–202
Saleh FH, Crotty KA, Hersey P, Menzies SW (2001) Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1. Int J Cancer 94:551–557
Aung PP, Nagarajan P, Prieto VG (2017) Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance. Lab Invest. https://doi.org/10.1038/labinvest.2017.8
Bae JM, Choi YY, Kim DS, Lee JH, Jang HS, Lee JH, Kim H, Oh BH, Roh MR, Nam KA, Chung KY (2015) Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 72:59–70
Rozeman EA, Dekker TJA, Haanen J, Blank CU (2018) Advanced melanoma: current treatment options, biomarkers, and future perspectives. Am J Clin Dermatol 19:303–317
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P et al (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372:2521–2532
Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375–384
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908–918
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A et al (2015) Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martin-Algarra S, Karaszewska B et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358–365
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107–114
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C et al (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386:444–451
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30–39
Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, Mandala M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867–1876
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C et al (2018) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19:603–615
Ascierto PA, Dummer R (2018) Immunological effects of BRAF+MEK inhibition. Oncoimmunology 7:e1468955
Jochems A, Schouwenburg MG, Leeneman B, Franken MG, van den Eertwegh AJ, Haanen JB, Gelderblom H, Uyl-de Groot CA, Aarts MJ, van den Berkmortel FW, Blokx WA, Cardous-Ubbink MC et al (2017) Dutch melanoma treatment registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands. Eur J Cancer 72:156–165
van Zeijl MCT, de Wreede LC, van den Eertwegh AJM, Wouters M, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel F, de Groot JWB, Hospers GAP, Kapiteijn E et al (2020) Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry. Eur J Cancer 144:242–251
Manola J, Atkins M, Ibrahim J, Kirkwood J (2000) Prognostic factors in metastatic melanoma: a pooled analysis of eastern cooperative oncology group trials. J Clin Oncol 18:3782–3793
van Zeijl MCT, Ismail RK, de Wreede LC, van den Eertwegh AJM, de Boer A, van Dartel M, Hilarius DL, Aarts MJB, van den Berkmortel F, Boers-Sonderen MJ, de Groot JB, Hospers GAP et al (2020) Real-world outcomes of advanced melanoma patients not represented in phase III trials. Int J Cancer 147:3461–3470
Scott JF, Gerstenblith MR. (2018) Noncutaneous Melanoma. Melanoma of Unknown Primary, Codon Publications, Singapore
Luen S, Wong SW, Mar V, Kelly JW, McLean C, McArthur GA, Haydon A (2018) Primary tumor thickness is a prognostic factor in stage iv melanoma: a retrospective study of primary tumor characteristics. Am J Clin Oncol 41:90–94
Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu WJ, McIntyre S, Hwu P (2008) Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 26:624–633
Lee CC, Faries MB, Wanek LA, Morton DL (2009) Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 27:3489–3495
Ellebaek E, Bastholt L, Schmidt H, Svane IM, Donia M (2019) The real-world outcome of metastatic melanoma: unknown primary vs. known cutaneous. Int J Cancer 145:3173–3174
Verver D, van der Veldt AAM, van Akkooi ACJ, Verhoef K, Grunhagen DJ, Louwman MWJ (2019) Author’s reply to: the real-world outcome of metastatic melanoma: unknown primary vs. known cutaneous. Int J Cancer 145:3175–3176
Gambichler T, Chatzipantazi M, Schröter U, Stockfleth E, Gedik C (2019) Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results. OncoImmunology 8:1677139
Dasgupta T, Bowden L, Berg JW (1963) Malignant melanoma of unknown primary origin. Surg Gynecol Obstet 117:341–345
Egberts F, Bergner I, Kruger S, Haag J, Behrens HM, Hauschild A, Rocken C (2014) Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas. Ann Oncol 25:246–250
Dutton-Regester K, Kakavand H, Aoude LG, Stark MS, Gartside MG, Johansson P, O’Connor L, Lanagan C, Tembe V, Pupo GM, Haydu LE, Schmidt CW et al (2013) Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. Pigment Cell Melanoma Res 26:852–860
Gos A, Jurkowska M, van Akkooi A, Robert C, Kosela-Paterczyk H, Koljenovic S, Kamsukom N, Michej W, Jeziorski A, Pluta P, Verhoef C, Siedlecki JA et al (2014) Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site. Ann Surg Oncol 21:4317–4323